DRKS00005070RecruitingNot Applicable
Translational examinations of the role of B-Lymphozyte stimulator (BLyS) in the pathophysiology of type 2 diabetes in humans
KSH, Campus KielKlinik für Innere Medizin 10 sites75 target enrollmentStarted: June 14, 2013Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 75
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to 80 Years (—)
- Sex
- All
Inclusion Criteria
- •1. obesity and/or type 2 diabetes
- •2. informed consent
- •3. men and women, 18-80 years of age
- •4. caucasian descent
Exclusion Criteria
- •1. lipodystrophy
- •2. oncological disease
- •3. LFT >3-fold of normal range
- •4. creatinin > 1.5 mg/dl
- •5. Hyper- or hypotcortisolism
- •6. Hyper- or hypothyreosis
- •7. known HIV, HBV oder HCV infektion
Investigators
Similar Trials
Completed
Not Applicable
Isolation and immune profiling of human B lymphocytes for the development of potential diagnostic and therapeutic antibodiesendometrial cancerUterine cancer10038594NL-OMON55081niversitair Medisch Centrum Groningen67
Recruiting
Not Applicable
Effects of body electrical stimulation after the stomach reduction surgeryMorbidly obese patients undergoing bariatric surgeryC18.654.726.500.700E02.065.062RBR-99qw5hniversidade Federal de São Carlos
Completed
Phase 2
Role of Sentinel Lymph Node in Early Stage Ovarian CancerCTRI/2022/06/043275AIIMS Rishikesh29
Completed
Not Applicable
The elucidation of the mechanism of the B-cell tolerance in the minor ABO-mismatched bone marrow transplantatioJPRN-UMIN000005842Keio University School of Medicine10
Recruiting
Phase 3
Single-cell deep phenotyping of B lymphocytes to personalize immunotherapy in patients with Myasthenia Gravis: clinical trial to evaluate the efficacy and safety of Rituximab in generalized AChR-antibody positive Myasthenia GravisGeneralized Myasthenia Gravis2024-518939-12-00Fondazione Policlinico Universitario Agostino Gemelli IRCCS40